Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 8:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transdermal patch Clear all
Completed Phase 2 Interventional

Safety and Efficacy Study of SUN 131 TDS as Compared to Placebo TDS in Adult Patients With a Chalazion

NCT02338648
View directory record Official record
Conditions
Chalazion
Interventions
SUN-131 1.5% TDS, Placebo TDS
Drug
Lead sponsor
Senju USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Santa Ana, California • Littleton, Colorado • Washington D.C., District of Columbia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Embedding Comprehensive Smoking Cessation Programs Into Community Clinics

NCT04717544
View directory record Official record
Conditions
Smoking Cessation
Interventions
Intervention Arm
Behavioral
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
406 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

Phase IV:Safety and Efficacy of EMSAM in Adolescents With Major Depression

NCT00531947
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Selegiline Transdermal System, Placebo
Drug
Lead sponsor
Somerset Pharmaceuticals
Industry
Eligibility
12 Years to 17 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
20
States / cities
Dothan, Alabama • National City, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System

NCT00916383
View directory record Official record
Conditions
Irritation/Irritant
Interventions
350 mg Donepezil Transdermal Patch, Placebo Patch
Drug
Lead sponsor
Teikoku Pharma USA, Inc.
Industry
Eligibility
65 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
7
States / cities
Phoenix, Arizona • Fresno, California • Garden Grove, California + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Delivering VergeRx at FQHCs

NCT06161675
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
QuitAid, SmokefreeTXT, Nicotine Replacement Therapy Patch, Nicotine lozenge
Behavioral · Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Oct 22, 2026, 8:40 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Proteomic Analysis of Sweat in Cutaneous Conditions

NCT02768090
View directory record Official record
Conditions
Application Site Perspiration
Interventions
Skin Patch
Device
Lead sponsor
Larkin Community Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hollywood, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Active, not recruiting Not applicable Interventional

Smoking Cessation Intervention for Cancer Patients

NCT00575718
View directory record Official record
Conditions
Newly Diagnosed Cancer Patients
Interventions
Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Behavioral Intervention for Low Income Depressed Smokers in Drug Treatment

NCT01372254
View directory record Official record
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

NCT00313014
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine, Oxycodone Immediate-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
85
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Results available

The END Perioperative Smoking Pilot Study

NCT02482233
View directory record Official record
Conditions
Smoking, Nicotine Addiction, Surgery
Interventions
ENDD (NJOY), NRT (NicoDerm CQ), telephone counseling, brief advice, brochure
Behavioral · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 3 Interventional Results available

Long-term Extension of RECOVER- Long-term Effect of the 24h Transdermal Delivery of Rotigotine in Subjects With Idiopathic Parkinson's Disease

NCT00519532
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Rotigotine
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
St. Petersburg, Florida • Salisbury, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Oct 22, 2026, 8:40 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Observing Performance of Haptic Vibrotactile Trigger Technology by Measuring Changes in Resting Metabolic Rate: Assessment and Analysis

NCT07781384
View directory record Official record
Conditions
Resting Metabolic Rate, Energy Metabolism, Haptic Technology, Vibrotactile Stimulation
Interventions
IGNITE Patch (Active), Inactive patch
Device
Lead sponsor
SuperPatch Limited LLC
Industry
Eligibility
18 Years to 85 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tyrone, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Osteoarthritis Pain

NCT00312221
View directory record Official record
Conditions
Osteoarthritis
Interventions
Buprenorphine, oxycodone immediate-release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
23
States / cities
Birmingham, Alabama • Chula Vista, California • Roseville, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Outcomes Mandate National Integration With Cannabis as Medicine

NCT03944447
View directory record Official record
Conditions
Chronic Pain, Chronic Pain Syndrome, Chronic Pain Due to Injury, Chronic Pain Due to Trauma, Fibromyalgia, Seizures, Hepatitis C, Cancer, Crohn Disease, HIV/AIDS, Multiple Sclerosis, Traumatic Brain Injury, Sickle Cell Disease, Post Traumatic Stress Disorder, Tourette Syndrome, Ulcerative Colitis, Glaucoma, Epilepsy, Inflammatory Bowel Diseases, Parkinson Disease, Amyotrophic Lateral Sclerosis, Chronic Traumatic Encephalopathy, Anxiety, Depression, Insomnia, Autism, Opioid-use Disorder, Bipolar Disorder, Covid19, SARS-CoV Infection, COVID-19, Corona Virus Infection, Coronavirus
Interventions
Cannabis, Medical, RYAH-Medtech Inhaler
Drug · Device
Lead sponsor
OMNI Medical Services, LLC
Network
Eligibility
7 Years and older
Enrollment
200,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2025
U.S. locations
17
States / cities
Boca Raton, Florida • Bradenton, Florida • Fort Lauderdale, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2022 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional

Innovations to Prevent Relapse Among Low-income African American Smokers

NCT03982576
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine replacement therapy (NRT), CS-CBT intervention, Path2Quit, Relapse prevention program, SmokefreeTXT
Other · Behavioral
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia

NCT05660525
View directory record Official record
Conditions
Smoking Cessation, Smoking, Cigarette, Smoking Reduction, Smoking, Smoking, Tobacco, Quitting Smoking
Interventions
4 weeks of Nicotine lozenge, 8 weeks of Nicotine Replacement Therapy Patch, QuitAid, Smokefree TXT, Tobacco Quitline, 4 weeks of Nicotine Replacement Therapy Patch, 8 Weeks Nicotine Lozenge
Drug · Behavioral
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers

Smoking Cessation Intervention

NCT03072511
View directory record Official record
Conditions
Smoking Cessation
Interventions
Spotlight on Smoke-Free Living: Mindsets and Decisions, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 23, 2020 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety & Efficacy of d-Amphetamine Transdermal System vs Placebo in Children & Adolescents With ADHD

NCT01711021
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
d-Amphetamine Transdermal Patch, Placebo patch
Drug
Lead sponsor
Noven Pharmaceuticals, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
3
States / cities
Irvine, California • Miami, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 22, 2026, 8:40 AM EDT
Recruiting Phase 4 Interventional

Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

NCT06733350
View directory record Official record
Conditions
Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Biopsy of Prostate, Biospecimen Collection, Magnetic Resonance Imaging, Patient Observation, Questionnaire Administration, Therapeutic Testosterone
Procedure · Other · Drug
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 1 Interventional Results available

Dose Titration Investigation of the Pharmacokinetics of Testosterone Transdermal Systems in Hypogonadal Men

NCT01104246
View directory record Official record
Conditions
Hypogonadism
Interventions
Testerone Transdermal System
Drug
Lead sponsor
Watson Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
3
States / cities
Miramar, Florida • Omaha, Nebraska • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

UW-CTRI Triple Medication Smoking Cessation Study

NCT02681510
View directory record Official record
Conditions
Smoking
Interventions
Varenicline, Nicotine Transdermal Patch, Nicotine Mini
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 11, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Dissemination of a Tailored Tobacco Quitline for Rural Veteran Smokers

NCT01892813
View directory record Official record
Conditions
Nicotine Dependence, Tobacco Use
Interventions
Nicotine replacement therapy - Transdermal nicotine patch, Nicotine replacement therapy - Nicotine gum, Nicotine replacement therapy - Nicotine lozenge, Bupropion, Varenicline, Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum, Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge, Combination pharmacotherapy - Transdermal nicotine patch + bupropion, Tobacco quitline referral, Tailored behavioral intervention, Alcohol use risk reduction, Behavioral activation for depressive symptoms, Behavioral management of postcessation weight gain
Drug · Behavioral
Lead sponsor
Mark Vander Weg
Other
Eligibility
18 Years to 99 Years
Enrollment
411 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Transdermal Patch to Monitor Inflammatory Biomarkers of GVHD

NCT02511782
View directory record Official record
Conditions
Graft Versus Host Disease
Interventions
D-SQUAME Skin Sampling Discs
Device
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
3 Months to 30 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 22, 2026, 8:40 AM EDT
Completed Phase 3 Interventional Results available

Safety, Pharmacokinetics (PK), and Efficacy of Buprenorphine Transdermal System (BTDS) in Children

NCT01324570
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine transdermal system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
7 Years to 16 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
22
States / cities
Long Beach, California • Los Angeles, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 22, 2026, 8:40 AM EDT